{"id":"https://openalex.org/W2737680693","doi":null,"title":"Growth inhibitory effects of trastuzumab, erlotinib, and bevacizumab are proportional to average cellular levels of HER2 expression in breast cancer cell lines, and the effects of combinations of the three are additive in cell lines with high HER2 expression","display_name":"Growth inhibitory effects of trastuzumab, erlotinib, and bevacizumab are proportional to average cellular levels of HER2 expression in breast cancer cell lines, and the effects of combinations of the three are additive in cell lines with high HER2 expression","publication_year":2006,"publication_date":"2006-04-15","ids":{"openalex":"https://openalex.org/W2737680693","mag":"2737680693"},"language":"en","primary_location":{"id":"mag:2737680693","doi":null,"is_oa":false,"landing_page_url":"https://cancerres.aacrjournals.org/content/66/8_Supplement/290.4","pdf_url":null,"source":{"id":"https://openalex.org/S168522863","display_name":"Cancer Research","issn_l":"0008-5472","issn":["0008-5472","1538-7445"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320273","host_organization_name":"American Association for Cancer Research","host_organization_lineage":["https://openalex.org/P4310320273"],"host_organization_lineage_names":["American Association for Cancer Research"],"type":"journal"},"license":null,"license_id":null,"version":null,"is_accepted":false,"is_published":false,"raw_source_name":"Cancer Research","raw_type":null},"volume":null,"type":"article","indexed_in":[],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5045254331","display_name":"David R. Emlet","orcid":"https://orcid.org/0000-0003-2131-9902","observed_orcids":["https://orcid.org/0000-0003-2131-9902"]},"institutions":[{"id":"https://openalex.org/I4210087180","display_name":"Allegheny-Singer Research Institute","ror":"https://ror.org/004315x41","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1310421338","https://openalex.org/I4210087180"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"David R. Emlet","raw_affiliation_strings":["Allegheny Singer research Institute, Pittsburgh, PA"],"raw_orcid":"https://orcid.org/0000-0003-2131-9902","affiliations":[{"raw_affiliation_string":"Allegheny Singer research Institute, Pittsburgh, PA","institution_ids":["https://openalex.org/I4210087180"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5106083403","display_name":"Agnese A. Pollice","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210087180","display_name":"Allegheny-Singer Research Institute","ror":"https://ror.org/004315x41","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1310421338","https://openalex.org/I4210087180"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Agnese A. Pollice","raw_affiliation_strings":["Allegheny Singer research Institute, Pittsburgh, PA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Allegheny Singer research Institute, Pittsburgh, PA","institution_ids":["https://openalex.org/I4210087180"]}]},{"author_position":"middle","author":{"id":null,"display_name":"Charles A. Smith","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210087180","display_name":"Allegheny-Singer Research Institute","ror":"https://ror.org/004315x41","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1310421338","https://openalex.org/I4210087180"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Charles A. Smith","raw_affiliation_strings":["Allegheny Singer research Institute, Pittsburgh, PA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Allegheny Singer research Institute, Pittsburgh, PA","institution_ids":["https://openalex.org/I4210087180"]}]},{"author_position":"middle","author":{"id":null,"display_name":"Kathryn Brown","orcid":"https://orcid.org/0000-0001-5710-1708","observed_orcids":["https://orcid.org/0000-0001-5710-1708"]},"institutions":[{"id":"https://openalex.org/I4210087180","display_name":"Allegheny-Singer Research Institute","ror":"https://ror.org/004315x41","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1310421338","https://openalex.org/I4210087180"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Kathryn Brown","raw_affiliation_strings":["Allegheny Singer research Institute, Pittsburgh, PA"],"raw_orcid":"https://orcid.org/0000-0001-5710-1708","affiliations":[{"raw_affiliation_string":"Allegheny Singer research Institute, Pittsburgh, PA","institution_ids":["https://openalex.org/I4210087180"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5091391677","display_name":"Deborah L. Kociban","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210087180","display_name":"Allegheny-Singer Research Institute","ror":"https://ror.org/004315x41","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1310421338","https://openalex.org/I4210087180"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Deborah L. Kociban","raw_affiliation_strings":["Allegheny Singer research Institute, Pittsburgh, PA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Allegheny Singer research Institute, Pittsburgh, PA","institution_ids":["https://openalex.org/I4210087180"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5027859218","display_name":"Stanley E. Shackney","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210087180","display_name":"Allegheny-Singer Research Institute","ror":"https://ror.org/004315x41","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1310421338","https://openalex.org/I4210087180"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Stanley E. Shackney","raw_affiliation_strings":["Allegheny Singer research Institute, Pittsburgh, PA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Allegheny Singer research Institute, Pittsburgh, PA","institution_ids":["https://openalex.org/I4210087180"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":1,"corresponding_author_ids":[],"corresponding_institution_ids":["https://openalex.org/I4210087180"],"apc_list":null,"apc_paid":null,"fwci":0.0,"has_fulltext":false,"cited_by_count":0,"citation_normalized_percentile":{"value":0.38239689,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":null,"biblio":{"volume":"66","issue":null,"first_page":"290","last_page":"291"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10755","display_name":"HER2/EGFR in Cancer Research","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10755","display_name":"HER2/EGFR in Cancer Research","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10183","display_name":"Breast Cancer Treatment Studies","score":0.0,"subfield":{"id":"https://openalex.org/subfields/1306","display_name":"Cancer Research"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10696","display_name":"Gastric Cancer Management and Outcomes","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2740","display_name":"Pulmonary and Respiratory Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/trastuzumab","display_name":"trastuzumab","score":0.8939999938011169},{"id":"https://openalex.org/keywords/erlotinib","display_name":"erlotinib","score":1.0},{"id":"https://openalex.org/keywords/bevacizumab","display_name":"bevacizumab","score":1.0},{"id":"https://openalex.org/keywords/her2-overexpression","display_name":"HER2 overexpression","score":0.871999979019165},{"id":"https://openalex.org/keywords/breast-cancer","display_name":"breast cancer","score":0.8190000057220459},{"id":"https://openalex.org/keywords/combination-therapy","display_name":"combination therapy","score":0.6669999957084656},{"id":"https://openalex.org/keywords/targeted-therapy","display_name":"targeted therapy","score":0.5709999799728394},{"id":"https://openalex.org/keywords/mcf-7-cells","display_name":"MCF-7 cells","score":0.8069999814033508},{"id":"https://openalex.org/keywords/cell-cycle-arrest","display_name":"cell cycle arrest","score":0.6639999747276306},{"id":"https://openalex.org/keywords/g1-cell-cycle-arrest","display_name":"G1 cell cycle arrest","score":0.6660000085830688},{"id":"https://openalex.org/keywords/igf-1-receptor","display_name":"IGF-1 receptor","score":0.7459999918937683},{"id":"https://openalex.org/keywords/egfr-amplification","display_name":"EGFR amplification","score":0.9760000109672546},{"id":"https://openalex.org/keywords/dose-response-relationship","display_name":"dose-response relationship","score":0.43700000643730164},{"id":"https://openalex.org/keywords/tumor-growth-inhibition","display_name":"tumor growth inhibition","score":0.6880000233650208}],"concepts":[{"id":"https://openalex.org/C2778087573","wikidata":"https://www.wikidata.org/wiki/Q418369","display_name":"Erlotinib","level":4,"score":0.9381381273269653},{"id":"https://openalex.org/C2779786085","wikidata":"https://www.wikidata.org/wiki/Q412616","display_name":"Trastuzumab","level":4,"score":0.8576682806015015},{"id":"https://openalex.org/C2779707156","wikidata":"https://www.wikidata.org/wiki/Q5611758","display_name":"Growth inhibition","level":3,"score":0.6626913547515869},{"id":"https://openalex.org/C2777802072","wikidata":"https://www.wikidata.org/wiki/Q413299","display_name":"Bevacizumab","level":3,"score":0.6284354329109192},{"id":"https://openalex.org/C502942594","wikidata":"https://www.wikidata.org/wiki/Q3421914","display_name":"Cancer research","level":1,"score":0.5233561396598816},{"id":"https://openalex.org/C62112901","wikidata":"https://www.wikidata.org/wiki/Q189159","display_name":"Cell growth","level":2,"score":0.5037826895713806},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.4829918146133423},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.4822274148464203},{"id":"https://openalex.org/C81885089","wikidata":"https://www.wikidata.org/wiki/Q189082","display_name":"Cell culture","level":2,"score":0.4807867407798767},{"id":"https://openalex.org/C553184892","wikidata":"https://www.wikidata.org/wiki/Q1141429","display_name":"Flow cytometry","level":2,"score":0.4478243887424469},{"id":"https://openalex.org/C2909325608","wikidata":"https://www.wikidata.org/wiki/Q418369","display_name":"Erlotinib Hydrochloride","level":5,"score":0.4264587461948395},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.3841835856437683},{"id":"https://openalex.org/C530470458","wikidata":"https://www.wikidata.org/wiki/Q128581","display_name":"Breast cancer","level":3,"score":0.37658149003982544},{"id":"https://openalex.org/C185592680","wikidata":"https://www.wikidata.org/wiki/Q2329","display_name":"Chemistry","level":0,"score":0.35189157724380493},{"id":"https://openalex.org/C2779438470","wikidata":"https://www.wikidata.org/wiki/Q424401","display_name":"Epidermal growth factor receptor","level":3,"score":0.3060970604419708},{"id":"https://openalex.org/C86803240","wikidata":"https://www.wikidata.org/wiki/Q420","display_name":"Biology","level":0,"score":0.2528831958770752},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.23619899153709412},{"id":"https://openalex.org/C203014093","wikidata":"https://www.wikidata.org/wiki/Q101929","display_name":"Immunology","level":1,"score":0.21487879753112793},{"id":"https://openalex.org/C2776694085","wikidata":"https://www.wikidata.org/wiki/Q974135","display_name":"Chemotherapy","level":2,"score":0.14898014068603516},{"id":"https://openalex.org/C55493867","wikidata":"https://www.wikidata.org/wiki/Q7094","display_name":"Biochemistry","level":1,"score":0.0},{"id":"https://openalex.org/C54355233","wikidata":"https://www.wikidata.org/wiki/Q7162","display_name":"Genetics","level":1,"score":0.0}],"mesh":[],"locations_count":1,"locations":[{"id":"mag:2737680693","doi":null,"is_oa":false,"landing_page_url":"https://cancerres.aacrjournals.org/content/66/8_Supplement/290.4","pdf_url":null,"source":{"id":"https://openalex.org/S168522863","display_name":"Cancer Research","issn_l":"0008-5472","issn":["0008-5472","1538-7445"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320273","host_organization_name":"American Association for Cancer Research","host_organization_lineage":["https://openalex.org/P4310320273"],"host_organization_lineage_names":["American Association for Cancer Research"],"type":"journal"},"license":null,"license_id":null,"version":null,"is_accepted":false,"is_published":false,"raw_source_name":"Cancer Research","raw_type":null}],"best_oa_location":null,"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being","score":0.9763000011444092}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W2124748060","https://openalex.org/W2099235206","https://openalex.org/W2887634622","https://openalex.org/W2053848912","https://openalex.org/W2964568020","https://openalex.org/W7097012505","https://openalex.org/W2032699899","https://openalex.org/W2092159470","https://openalex.org/W2741171153","https://openalex.org/W2117019982"],"abstract_inverted_index":{"1229":[0],"MCF-7":[3],"cells":[4,150,227,271],"were":[5,12,28,196],"transfected":[6],"with":[7,172,179,218,231,272],"HER2":[8,18,80,173,276],"and":[9,26,35,48,102,104,128,153,189,201,220,248,260],"cell":[10,40,85,115,124,134],"sublines":[11],"selected":[13],"for":[14,23,100,106,209,269],"graded":[15],"levels":[16,44,50,78,274],"of":[17,32,54,79,149,164,170,245,255,275],"overexpression.":[19],"Dose":[20],"response":[21,171],"curves":[22],"trastuzumab,":[24,199,246],"erlotinib,":[25,200,247],"bevacizumab":[27,249],"obtained":[29],"in":[30,36,82,93,151,160,205,225],"each":[31,71,108],"these":[33,123,133,256],"sublines,":[34],"established":[37],"breast":[38],"cancer":[39],"lines":[41,116,125,135],"expressing":[42],"low":[43],"(parental":[45],"MCF-7,":[46],"MDA-231),":[47],"high":[49,113,273],"(SKBR-3,":[51],"BT474,":[52],"NH27)":[53],"HER2,":[55,195],"using":[56],"tumor":[57,270],"growth":[58,68,216,263],"inhibition":[59,69,217],"as":[60],"an":[61,161],"endpoint.":[62],"At":[63],"all":[64],"drug":[65,72,88],"concentrations":[66,89],"tested,":[67],"by":[70,117,126,136],"was":[73,176,228],"proportional":[74],"to":[75,91,155,198],"the":[76,83,94,112,129,144,168,243],"average":[77],"expression":[81,174],"different":[84],"lines.":[86],"Using":[87],"estimated":[90],"be":[92],"clinically":[95],"relevant":[96],"range":[97],"(1":[98],"mg/ml":[99],"trastuzumab":[101],"bevacizumab,":[103,202],"500nM":[105],"erlotinib)":[107],"targeted":[109,257],"agent":[110],"inhibited":[111,122,132,147],"HER2-expressing":[114],"30-50%.":[118],"All":[119],"two-agent":[120],"combinations":[121],"50-70%,":[127],"three-agent":[130],"combination":[131,146,244],"70-85%.":[137],"Serial":[138],"flow":[139],"cytometry":[140],"studies":[141],"showed":[142],"that":[143,242,261],"triple":[145],">20%":[148],"G1,":[152],"led":[154],"delayed":[156],"S":[157,235],"phase":[158,236],"progression":[159,237],"additional":[162],"\u223c30%":[163],"cells.":[165],"By":[166],"comparison,":[167],"correlation":[169],"level":[175],"not":[177,193,229],"observed":[178],"anti-IGF1":[180],"receptor":[181],"therapy.":[182],"Rb":[183],"dysfunctional":[184],"tumors":[185],"(MDA-468,":[186],"BT549,":[187],"DU4475,":[188],"MDA-436)":[190],"which":[191,213],"do":[192],"overexpress":[194],"unresponsive":[197],"singly":[203],"or":[204,234],"any":[206,254],"combination,":[207],"except":[208],"EGFR-amplified":[210],"MDA-468":[211,226],"cells,":[212],"exhibited":[214],"\u223c25%":[215],"erlotinib":[219],"erlotinib-containing":[221],"combinations.":[222],"Drug":[223],"effect":[224],"associated":[230],"G1":[232],"arrest":[233],"delay.":[238],"These":[239],"findings":[240],"indicate":[241],"is":[250],"more":[251],"potent":[252],"than":[253],"agents":[258],"individually,":[259],"its":[262],"inhibitory":[264],"effects":[265],"are":[266],"highly":[267],"selective":[268],"expression.":[277]},"counts_by_year":[],"updated_date":"2026-10-14T16:39:01.820549","created_date":"2017-07-31T00:00:00"}